Loading...
XTAI1786
Market cap211mUSD
Dec 26, Last price  
96.30TWD
1D
2.12%
1Q
-25.06%
Jan 2017
99.21%
IPO
98.39%
Name

SciVision Biotech Inc

Chart & Performance

D1W1MN
XTAI:1786 chart
P/E
38.86
P/S
9.70
EPS
2.48
Div Yield, %
1.93%
Shrs. gr., 5y
5.09%
Rev. gr., 5y
16.69%
Revenues
713m
+27.93%
15,682,00066,215,000143,271,000200,680,000200,509,000158,281,000264,842,000228,304,000258,418,000329,581,000437,873,000466,881,000505,539,000557,348,000712,988,000
Net income
178m
+25.53%
-52,535,000-6,864,00051,161,00062,430,00040,352,000-22,145,00054,840,000-26,263,00017,139,00086,869,000120,703,000128,005,000101,720,000141,716,000177,900,000
CFO
272m
+52.64%
-36,088,0006,847,00037,127,00051,517,00037,275,0001,852,00049,807,00038,286,00015,978,000111,699,000204,400,000126,470,00098,507,000178,207,000272,012,000
Dividend
Jul 26, 20242.28227 TWD/sh
Earnings
Jun 26, 2025

Profile

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.
URL
https://www.scivision.com.tw/
IPO date
Dec 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
712,988
27.93%
557,348
10.25%
505,539
8.28%
Cost of revenue
513,350
422,737
383,597
Unusual Expense (Income)
NOPBT
199,638
134,611
121,942
NOPBT Margin
28.00%
24.15%
24.12%
Operating Taxes
32,097
31,834
14,335
Tax Rate
16.08%
23.65%
11.76%
NOPAT
167,541
102,777
107,607
Net income
177,900
25.53%
141,716
39.32%
101,720
-20.53%
Dividends
(133,301)
(93,830)
(58,556)
Dividend yield
2.25%
2.32%
1.66%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,216
5,260
306,888
Long-term debt
370,767
436,089
358,203
Deferred revenue
Other long-term liabilities
41,949
48,379
57,941
Net debt
(432,073)
(147,678)
(47,092)
Cash flow
Cash from operating activities
272,012
178,207
98,507
CAPEX
(14,734)
(14,964)
(25,775)
Cash from investing activities
(213,365)
49,593
(77,005)
Cash from financing activities
(134,530)
(299,714)
240,058
FCF
238,896
190,335
69,149
Balance
Cash
804,056
673,887
695,841
Long term investments
(84,860)
16,342
Excess cash
768,407
561,160
686,906
Stockholders' equity
947,797
886,136
825,086
Invested Capital
1,247,960
1,400,227
1,456,285
ROIC
12.65%
7.20%
7.57%
ROCE
9.90%
6.86%
5.69%
EV
Common stock shares outstanding
76,442
74,658
70,978
Price
77.60
43.17%
54.20
9.27%
49.60
-12.78%
Market cap
5,931,899
46.59%
4,046,464
14.94%
3,520,509
-12.71%
EV
5,499,826
3,898,786
3,473,417
EBITDA
262,769
196,669
174,965
EV/EBITDA
20.93
19.82
19.85
Interest
8,220
6,458
8,066
Interest/NOPBT
4.12%
4.80%
6.61%